• PatientSafe Solutions

  Participated · Equity · Sep 2017

  PatientSafe Solutions builds the PatientTouch® mobile platform to unify clinical communications with critical workflows in a single application. PatientTouch consolidates text, talk, alerts, EMR data, clinical workflows and customizable care interventions into one mobile app that extends an organization’s EHR and clinical infrastructure. The company reports that PatientTouch is used by more than 80 leading healthcare institutions and has helped clinicians both in and outside the hospital streamline care delivery, increase quality, and lower costs. Founded in 2002 and based in San Diego, PatientSafe plans to use newly raised funding to scale operations, accelerate sales and customer success, and drive further innovation in clinical communications and care delivery. Leadership also plans to expand go-to-market capabilities and identify product acquisition opportunities to strengthen its enterprise offerings. PatientSafe emphasizes delivering measurable safety and quality improvements and building a patient-centric communications and workflow network that unifies the patient, family, and care team across the continuum of care. PatientSafe Solutions develops the PatientTouch system, a smart point-of-care mobile platform that pairs customized Apple hardware (eMMA handheld) with software to improve clinician workflow and ensure accurate medication administration. PatientTouch consolidates EHR data into a single mobile system and includes features such as barcode positive patient identification (PPID), streamlined mobile data entry, voice-over-IP communication, HIPAA-compliant messaging, and a unified task/inbox. The company reports over 75 implementations in the United States and says the PatientTouch system has supported over 300 million medication administrations; its Blood Product Administration module has received FDA 510(k) clearance. PatientSafe has recently expanded into the Asia Pacific market and received an investment from EDBI. The company is pursuing further international growth via partnerships and reseller agreements, including an exclusive Canadian reseller arrangement with TELUS Health. Management positions the technology as a tool to reduce costs, improve clinical productivity, and drive better patient outcomes. PatientSafe Solutions develops the PatientTouch System, a smart point-of-care mobile solution that integrates Apple iPhone 5 and iPod touch hardware with software to improve clinician workflow, medication administration accuracy, and care coordination. Capabilities include barcode positive patient identification (PPID), streamlined mobile data entry, voice-over-IP communication and HIPAA-compliant text messaging, a unified task and interventions inbox, and respiratory therapy workflows. Its PatientTouch Blood Product Administration module documents and verifies blood transfusions and phlebotomy specimens and received FDA 510(k) clearance. The company intends to use new capital to drive further U.S. adoption and expand into the Asia Pacific healthcare market. As part of APAC expansion, PatientSafe will consolidate hardware manufacturing and its global supply chain in Singapore and establish a local presence to support product innovation and commercialization, while keeping primary product development and design teams in San Diego. The company is led by president and CEO Joe Condurso. PatientSafe Solutions, based in San Diego, develops smart point-of-care mobile solutions for hospitals and health systems. Its flagship PatientTouch platform includes a series of clinical workflow and documentation applications such as barcode positive patient identification (PPID), patient-centric care interventions, clinical communications, and collaboration. The company says its products enhance patient safety, optimize EMR investment, and increase clinician efficiency and satisfaction. PatientSafe closed a $20 million Series C to drive hospital and health system adoption of its mobile solutions. Future planned mobile products will focus on delivering more value under Meaningful Use guidelines, Value-Based Purchasing programs, and on cost removal for health care systems. The company has received recognition in industry lists, including Wall Street Journal and Forbes rankings in 2011–2012. PatientSafe Solutions is a San Diego–based designer of integrated hardware and software patient safety solutions intended to reduce hospital-based medical errors. The company is developing the PatientTouch System, a platform aimed at providing a last line of defense against preventable errors at the point of care. PatientTouch targets medication errors, hospital-acquired infections and patient falls by optimizing clinician workflows and enabling patient engagement. The new funds will be used to complete development of the PatientTouch System and to further commercialize PatientSafe’s solutions in the U.S. hospital market. The company presents its offering as a combination of clinician workflow optimization and patient engagement tools to address safety gaps at bedside. The firm reported closing a financing to advance product development and commercialization.

• Gamma Medica

  Participated · Equity · Oct 2014

  Gamma Medica develops advanced digital molecular imaging technologies and commercializes the FDA‑approved LumaGEM Molecular Breast Imaging (MBI) system. LumaGEM is a fully digital, dual‑head, solid‑state CZT MBI system intended for women with complex breast anatomy, such as dense breast tissue, where mammography and ultrasound can miss early cancers. The system detects lesions as small as five millimeters and has demonstrated sensitivity and specificity equivalent to MRI at a fraction of the cost. LumaGEM is currently in use at premier hospitals and breast centers throughout the U.S. and has won awards including the 2014 Frost & Sullivan Product Leadership Award and the 2014 Medical Design Excellence Award. Gamma Medica announced $11.5 million in new growth financing—$6.5M from Hercules Technology Growth Capital and $5.0M from existing investor Psilos Group—to fund increased sales and marketing and accelerate global adoption of MBI. Management says the capital will power commercial expansion and further LumaGEM's clinical adoption worldwide. Gamma Medica designs, builds and services the LumaGEM® Molecular Breast Imaging (MBI) system and the companion LumaGUIDE® MBI-guided biopsy module, a fully digital, FDA-cleared planar dual-head imaging system using cadmium zinc telluride (CZT) technology. LumaGEM highlights tumors obscured by dense breast tissue and is intended as an effective secondary diagnostic tool for radiologists, with reported >90% sensitivity and specificity as an adjunct to mammography. The company positions MBI as a lower-cost alternative with comparable sensitivity and improved specificity relative to MRI for dense-breast and high-risk cases. Gamma Medica plans to expand commercialization of MBI and use proceeds to fund additional multi-site post-market clinical studies with several leading U.S. academic research institutions. The article notes regulatory and market tailwinds, including state laws requiring patient notification about dense breast tissue that can reduce mammography sensitivity. Financially, Gamma Medica announced a $16 million Series A financing from Psilos, which has now invested more than $20 million in the company to date. Gamma Medica develops clinical and pre-clinical imaging systems, most notably the LumaGEM® Molecular Breast Imaging (MBI) System for breast diagnostics and the Triumph™ II trimodality system for small-animal imaging. The LumaGEM MBI system is FDA-cleared, utilizes CZT solid‑state detectors, and has been installed in more than 20 clinical and research facilities in the U.S. and Europe. Radiologists use LumaGEM as an adjunct to mammography, particularly for detecting lesions in dense breast tissue; published Mayo Clinic studies cited in the article report sensitivity of 91% and specificity of 93%. The company emphasizes that LumaGEM reimbursement is about half the cost of an MRI and that images are easier and faster to read. Gamma Medica also markets industry‑leading preclinical imaging products featuring solid‑state SPECT and PET technologies. Financially, the company entered Chapter 11 and secured interim financing to pursue either a reorganization or an asset sale while refocusing operations and making management changes.

• CarePort Health

  Participated · Seed · Mar 2013

  Careport Health offers a platform for hospitals to help patients understand and select post-acute care options. The platform collects and analyzes data from post-acute care organizations to identify providers that match a patient’s clinical needs and preferences. It surfaces facilities that meet criteria such as low readmission rates and presents the most relevant options rather than a simple printout. Careport also tracks patients’ recovery and transmits relevant information to the patient’s care team. The company raised $2 million to accelerate growth of the business, which the article describes as a two-year-old business. CEO Lissy Hu founded the company in 2013 while she was a Harvard Medical School student. Careport Health’s core product lets a nurse enter a patient’s insurance information, search facility listings that meet criteria, and make an immediate bed reservation. The company launched its first pilot at Massachusetts General Hospital in January with 2,000 beds in the reservation system and has since grown that inventory to 4,000 beds. Today it is focused on post-acute care and expects hospitals to pay to use the service. Patients and caregivers can also search provider listings by services or neighborhood. Longer-term plans include becoming a one-stop shop for patient transitions, including reserving durable medical equipment. Careport’s team includes CEO and co-founder Lissy Hu and co-founder Gretchen Fuller, and the company has participated in TechStars and Mass Challenge; it closed a $900,000 seed round.

• SeeChange Health

  Participated · Series C · Jan 2013

  SeeChange Health is a San Francisco, CA–based provider of benefit design solutions delivering a Software as a Service (SaaS) platform. Led by CEO Martin Watson, the platform enables health plans and self-funded employers to offer customized engagement and incentive programs to motivate employees to improve their health. The SaaS solution integrates with any health plan or TPA’s existing technologies and applications. The company raised $15m in Series C financing and intends to use the capital to expand into new markets and to advance ongoing product development. Backers in the round include existing investors Psilos Group and Maverick Capital. SeeChange Health helps employers and health plans manage health and reduce health care costs through value-based health management solutions. Led by CEO Martin Watson, the company creates Personalized Health Actions Plans based on an employee’s health status and rewards individuals for completing a Health Questionnaire, a Biometric Screening, and Health Actions. Its core product pairs personalized action plans with incentive programs to drive screenings and health-related activities. The company has raised $20M in a Series B financing and intends to use the funds to further expand product development efforts. Investors named in the round include new backer Maverick Capital and existing shareholder Psilos Group.

• AngioScore

  Participated · Equity · Apr 2011

  AngioScore develops the AngioSculpt Percutaneous Transluminal Coronary and Peripheral Angioplasty (PTCA/PTA) scoring balloon catheters. The company has received regulatory clearance to market its Coronary and Peripheral AngioSculpt catheters in the U.S., Europe and Japan. AngioSculpt catheters have been used in more than 100,000 procedures worldwide, and the company cites a market of well over 3 million annual angioplasty procedures globally. AngioScore is pursuing product expansion with programs including a 100mm AngioSculpt for peripheral artery disease, a drug-coated AngioSculpt, and a variant for valvuloplasty and to facilitate TAVI procedures. Management says the financing will support these new product development programs and further enhance the company’s revenue growth over recent years. The company is privately held and located in Fremont, California.

No current team members are available.